Cardiovascular biomarkers in patients with COVID-19

Abstract The coronavirus disease 2019 (COVID-19) pandemic has increased awareness that severe acute respiratory distress syndrome coronavirus-2 (SARS-CoV-2) may have profound effects on the cardiovascular system. COVID-19 often affects patients with pre-existing cardiac disease, and may trigger acute respiratory distress syndrome (ARDS), venous thromboembolism (VTE), acute myocardial infarction (AMI), and acute heart failure (AHF). However, as COVID-19 is primarily a respiratory infectious disease, there remain substantial uncertainty and controversy whether and how cardiovascular biomarkers should be used in patients with suspected COVID-19. To help clinicians understand the possible value as well as the most appropriate interpretation of cardiovascular biomarkers in COVID-19, it is important to highlight that recent findings regarding the prognostic role of cardiovascular biomarkers in patients hospitalized with COVID-19 are similar to those obtained in studies for pneumonia and ARDS in general. Cardiovascular biomarkers reflecting pathophysiological processes involved in COVID-19/pneumonia and its complications have a role evaluating disease severity, cardiac involvement, and risk of death in COVID-19 as well as in pneumonias caused by other pathogens. First, cardiomyocyte injury, as quantified by cardiac troponin concentrations, and haemodynamic cardiac stress, as quantified by natriuretic peptide concentrations, may occur in COVID-19 as in other pneumonias. The level of those biomarkers correlates with disease severity and mortality. Interpretation of cardiac troponin and natriuretic peptide concentrations as quantitative variables may aid in risk stratification in COVID-19/pneumonia and also will ensure that these biomarkers maintain high diagnostic accuracy for AMI and AHF. Second, activated coagulation as quantified by D-dimers seems more prominent in COVID-19 as in other pneumonias. Due to the central role of endothelitis and VTE in COVID-19, serial measurements of D-dimers may help physicians in the selection of patients for VTE imaging and the intensification of the level of anticoagulation from prophylactic to slightly higher or even therapeutic doses.

[1]  E. Romano.  Association of Cardiac Injury with Mortality in Hospitalized Patients with COVID-19. , 2021, Arquivos brasileiros de cardiologia.

[2]  T. Omland,et al.  Growth Differentiation Factor 15 Provides Prognostic Information Superior to Established Cardiovascular and Inflammatory Biomarkers in Unselected Patients Hospitalized With COVID-19 , 2020, Circulation.

[3]  S. Yusuf,et al.  Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation , 2020, European heart journal.

[4]  S. Rizzo,et al.  Pathological features of COVID-19-associated myocardial injury: a multicentre cardiovascular pathology study , 2020, European heart journal.

[5]  Deepak L. Bhatt,et al.  2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. , 2020, European heart journal.

[6]  A. Cohen,et al.  Pulmonary embolism in COVID-19 patients: a French multicentre cohort study , 2020, European heart journal.

[7]  A. Jaffe,et al.  Cardiac Troponin for Assessment of Myocardial Injury in COVID-19 , 2020, Journal of the American College of Cardiology.

[8]  M. Parohan,et al.  Cardiac injury is associated with severe outcome and death in patients with Coronavirus disease 2019 (COVID-19) infection: A systematic review and meta-analysis of observational studies , 2020, European heart journal. Acute cardiovascular care.

[9]  Kipp W. Johnson,et al.  Prevalence and Impact of Myocardial Injury in Patients Hospitalized With COVID-19 Infection , 2020, Journal of the American College of Cardiology.

[10]  S. Cao,et al.  Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019 , 2020, European heart journal.

[11]  Cunming Liu,et al.  Deleterious effects of viral pneumonia on cardiovascular system. , 2020, European heart journal.

[12]  M. Aepfelbacher,et al.  Autopsy Findings and Venous Thromboembolism in Patients With COVID-19 , 2020, Annals of Internal Medicine.

[13]  K. Mertz,et al.  Postmortem examination of COVID‐19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction , 2020, Histopathology.

[14]  Catherine Klersy,et al.  Out-of-Hospital Cardiac Arrest during the Covid-19 Outbreak in Italy , 2020, The New England journal of medicine.

[15]  C. Roy,et al.  Acute Pulmonary Embolism in COVID-19 Patients on CT Angiography and Relationship to D-Dimer Levels , 2020, Radiology.

[16]  M. Ramakers,et al.  High incidence of venous thromboembolic events in anticoagulated severe COVID‐19 patients , 2020, Journal of Thrombosis and Haemostasis.

[17]  Holger Moch,et al.  Endothelial cell infection and endotheliitis in COVID-19 , 2020, The Lancet.

[18]  Christian Templin,et al.  Typical takotsubo syndrome triggered by SARS-CoV-2 infection , 2020, European heart journal.

[19]  D. Gommers,et al.  Incidence of thrombotic complications in critically ill ICU patients with COVID-19 , 2020, Thrombosis Research.

[20]  Feng Wang,et al.  Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia , 2020, Journal of Thrombosis and Haemostasis.

[21]  N. Mills,et al.  High-Sensitivity Cardiac Troponin Can Be An Ally in the Fight Against COVID-19. , 2020, Circulation.

[22]  M. Huang,et al.  Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2 , 2020, Journal of Thrombosis and Thrombolysis.

[23]  M. Hind,et al.  Respiratory management in severe acute respiratory syndrome coronavirus 2 infection , 2020, European heart journal. Acute cardiovascular care.

[24]  Dengju Li,et al.  Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy , 2020, Journal of Thrombosis and Haemostasis.

[25]  Roberto Maroldi,et al.  Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). , 2020, JAMA cardiology.

[26]  W. Gong,et al.  Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. , 2020, JAMA cardiology.

[27]  A. Falanga,et al.  ISTH interim guidance on recognition and management of coagulopathy in COVID‐19 , 2020, Journal of Thrombosis and Haemostasis.

[28]  Allan Schwartz,et al.  COVID-19 and Cardiovascular Disease , 2020, Circulation.

[29]  O. Pfister,et al.  SARS-CoV2: should inhibitors of the renin–angiotensin system be withdrawn in patients with COVID-19? , 2020, European heart journal.

[30]  H. Katus,et al.  Diagnostic performance of D-dimer in predicting venous thromboembolism and acute aortic dissection. , 2020, European heart journal. Acute cardiovascular care.

[31]  X. Bian,et al.  [A pathological report of three COVID-19 cases by minimally invasive autopsies]. , 2020, Zhonghua bing li xue za zhi = Chinese journal of pathology.

[32]  Qiurong Ruan,et al.  Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China , 2020, Intensive Care Medicine.

[33]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[34]  K. Yuen,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.

[35]  Dengju Li,et al.  Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia , 2020, Journal of Thrombosis and Haemostasis.

[36]  Jiyuan Zhang,et al.  Pathological findings of COVID-19 associated with acute respiratory distress syndrome , 2020, The Lancet Respiratory Medicine.

[37]  Yan Zhao,et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.

[38]  Ting Yu,et al.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.

[39]  M. Humbert,et al.  2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): supplementary data , 2019 .

[40]  Ye-ming Wang,et al.  Association Between Cardiac Injury and Mortality in Hospitalized Patients Infected With Avian Influenza A (H7N9) Virus , 2020, Critical care medicine.

[41]  F. D’Aragon,et al.  Diagnosis of Pulmonary Embolism with d-Dimer Adjusted to Clinical Probability. , 2019, The New England journal of medicine.

[42]  G. Filippatos,et al.  Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations , 2019, European journal of heart failure.

[43]  P. Amarenco,et al.  Five-Year Risk of Stroke after TIA or Minor Ischemic Stroke. , 2018, The New England journal of medicine.

[44]  A. von Eckardstein,et al.  Impact of age on the performance of the ESC 0/1h-algorithms for early diagnosis of myocardial infarction , 2018, European heart journal.

[45]  E. Vicaut,et al.  Five‐Year Risk of Stroke after TIA or Minor Ischemic Stroke , 2018, The New England journal of medicine.

[46]  Marco Valgimigli,et al.  2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). , 2018, European heart journal.

[47]  A. von Eckardstein,et al.  0/1-Hour Triage Algorithm for Myocardial Infarction in Patients With Renal Dysfunction , 2017, Circulation.

[48]  A. Jaffe,et al.  How to use D-dimer in acute cardiovascular care , 2017, European heart journal. Acute cardiovascular care.

[49]  Ò. Miró,et al.  Characterization of the observe zone of the ESC 2015 high-sensitivity cardiac troponin 0h/1h-algorithm for the early diagnosis of acute myocardial infarction. , 2016, International journal of cardiology.

[50]  A. Jaffe,et al.  Significance of elevated cardiac troponin T levels in critically ill patients with acute respiratory disease. , 2010, The American journal of medicine.

[51]  M. Christ-Crain,et al.  Use of B‐type natriuretic peptide in the risk stratification of community‐acquired pneumonia , 2008, Journal of internal medicine.

[52]  C. Schindler,et al.  Use of B-type natriuretic peptide in the management of acute dyspnea in patients with pulmonary disease. , 2006, American heart journal.

[53]  R. Hubbard,et al.  Risk of myocardial infarction and stroke after acute infection or vaccination. , 2004, The New England journal of medicine.

[54]  Ro,et al.  Direct Comparison of High-Sensitivity Cardiac Troponin T and I for Prediction of Mortality in Patients with Pneumonia , 2019 .